EYEN vs. GTHX, RIGL, GALT, ATOS, SGMT, RZLT, ALIM, PRQR, MCRB, and RGLS
Should you be buying Eyenovia stock or one of its competitors? The main competitors of Eyenovia include G1 Therapeutics (GTHX), Rigel Pharmaceuticals (RIGL), Galectin Therapeutics (GALT), Atossa Therapeutics (ATOS), Sagimet Biosciences (SGMT), Rezolute (RZLT), Alimera Sciences (ALIM), ProQR Therapeutics (PRQR), Seres Therapeutics (MCRB), and Regulus Therapeutics (RGLS). These companies are all part of the "pharmaceutical preparations" industry.
Eyenovia (NASDAQ:EYEN) and G1 Therapeutics (NASDAQ:GTHX) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their community ranking, profitability, earnings, valuation, media sentiment, analyst recommendations, risk, institutional ownership and dividends.
25.8% of Eyenovia shares are owned by institutional investors. Comparatively, 24.2% of G1 Therapeutics shares are owned by institutional investors. 7.1% of Eyenovia shares are owned by company insiders. Comparatively, 6.1% of G1 Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Eyenovia has higher earnings, but lower revenue than G1 Therapeutics. G1 Therapeutics is trading at a lower price-to-earnings ratio than Eyenovia, indicating that it is currently the more affordable of the two stocks.
In the previous week, G1 Therapeutics had 10 more articles in the media than Eyenovia. MarketBeat recorded 12 mentions for G1 Therapeutics and 2 mentions for Eyenovia. Eyenovia's average media sentiment score of 1.43 beat G1 Therapeutics' score of 0.74 indicating that Eyenovia is being referred to more favorably in the media.
G1 Therapeutics received 140 more outperform votes than Eyenovia when rated by MarketBeat users. Likewise, 66.10% of users gave G1 Therapeutics an outperform vote while only 65.13% of users gave Eyenovia an outperform vote.
Eyenovia has a beta of 1.73, suggesting that its stock price is 73% more volatile than the S&P 500. Comparatively, G1 Therapeutics has a beta of 1.71, suggesting that its stock price is 71% more volatile than the S&P 500.
Eyenovia currently has a consensus target price of $10.00, suggesting a potential upside of 1,137.62%. G1 Therapeutics has a consensus target price of $8.67, suggesting a potential upside of 162.63%. Given Eyenovia's stronger consensus rating and higher probable upside, equities research analysts clearly believe Eyenovia is more favorable than G1 Therapeutics.
Eyenovia has a net margin of 0.00% compared to G1 Therapeutics' net margin of -36.40%. G1 Therapeutics' return on equity of -74.75% beat Eyenovia's return on equity.
Summary
Eyenovia beats G1 Therapeutics on 9 of the 16 factors compared between the two stocks.
Get Eyenovia News Delivered to You Automatically
Sign up to receive the latest news and ratings for EYEN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding EYEN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Eyenovia Competitors List
Related Companies and Tools
